Shareholder Alert: The Ademi Firm investigates whether Ventyx Biosciences, Inc. is obtaining a Fair Price for its Public Shareholders

Core Viewpoint - Ademi LLP is investigating Ventyx for potential breaches of fiduciary duty and other legal violations related to its transaction with Eli Lilly, which involves a cash offer of $14.00 per share, valuing the deal at approximately $1.2 billion [1][2]. Group 1: Transaction Details - Ventyx stockholders will receive $14.00 per share in an all-cash transaction valued at around $1.2 billion [2]. - The transaction agreement includes provisions that significantly limit competing offers for Ventyx, imposing penalties if a competing bid is accepted [3]. Group 2: Board Conduct and Shareholder Rights - The investigation focuses on the conduct of Ventyx's board of directors to determine if they are fulfilling their fiduciary duties to all shareholders [3]. - Ademi LLP specializes in shareholder litigation related to buyouts, mergers, and individual shareholder rights [4].